ARDS Projected Dividend Yield

Aridis Pharmaceuticals Inc ( OTCBB : ARDS )

Aridis Pharmaceuticals is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using human monoclonal antibodies (mAbs) to treat infections. Co.'s product candidates include: AR-301, which is a human immunoglobulin 1 (IgG1) mAb targeting the gram-positive bacteria S. aureus alphatoxin; AR-320, which is a human, IgG1 monoclonal antibody targeting S. aureus alpha toxin; AR-501 (Panaecin), which is a spectrum small molecule anti-infective Co. is developing in addition to its targeted mAb product candidates; and AR-701, which is a is a cocktail of human mAbs that are directed at multiple protein epitopes on the SARS-CoV-2 virus.

20 YEAR PERFORMANCE RESULTS